Literature DB >> 2872826

Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases.

W K Goodman, D S Charney, L H Price, S W Woods, G R Heninger.   

Abstract

The effectiveness of clonidine hydrochloride in the treatment of abrupt withdrawal from long-term, therapeutic doses of benzodiazepines was studied in three patients under double-blind, placebo-controlled conditions. The intensity, severity, and duration of the abstinence syndrome were not altered by clonidine at a dose sufficient to markedly reduce blood pressure and plasma free 3-methoxy-4-hydroxyphenylglycol. These results contrast with the established efficacy of clonidine in the opiate withdrawal syndrome and suggest that many of the symptoms of benzodiazepine withdrawal may not be caused by hyperactivity of the noradrenergic system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872826     DOI: 10.1176/ajp.143.7.900

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  6 in total

1.  Treatment of benzodiazepine withdrawal symptoms with carbamazepine.

Authors:  D Garcia-Borreguero; T Bronisch; S Apelt; A Yassouridis; H M Emrich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

Review 2.  Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-01-03       Impact factor: 2.953

3.  Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome.

Authors:  E Schweizer; W G Case; F Garcia-Espana; D J Greenblatt; K Rickels
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

Review 4.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

5.  BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties.

Authors:  T P Blackburn; G S Baxter; G A Kennett; F D King; D C Piper; G J Sanger; D R Thomas; N Upton; M D Wood
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 6.  Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation.

Authors:  Dimy Fluyau; Neelambika Revadigar; Brittany E Manobianco
Journal:  Ther Adv Psychopharmacol       Date:  2018-02-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.